Radixin mRNA (RDX mRNA)

Radixin (RDX) mRNA is the transcript encoding Radixin, a member of the Ezrin-Radixin-Moesin (ERM) protein family that functions as a molecular bridge between the actin cytoskeleton and the plasma membrane (UniProt P35241). It plays a critical role in maintaining cell polarity, adhesion, and signal transduction, and is particularly essential in the liver for the proper apical localization of the multidrug resistance-associated protein 2 (MRP2), which facilitates bile salt transport (PubMed: 11893744). In various malignancies, including gastric and pancreatic cancers, RDX mRNA is frequently overexpressed, where it promotes epithelial-mesenchymal transition (EMT), cell invasion, and metastasis (PubMed: 24510066, 21602877). Conversely, loss-of-function mutations in the RDX gene are a known cause of autosomal recessive non-syndromic hearing loss, DFNB24 (NCBI Gene: 5962). Therapeutic targeting of RDX mRNA primarily involves the use of RNA interference (siRNA) or antisense oligonucleotides (ASOs) to knockdown protein levels in cancer cells to inhibit their metastatic potential. However, such interventions carry significant safety risks, most notably the potential for inducing cholestasis or liver injury due to the disruption of Radixin-dependent transport processes in hepatocytes. Additionally, the high structural homology between Radixin and other ERM proteins like Ezrin and Moesin poses a challenge for achieving high specificity with RNA-based therapies.

Other names

Radixin messenger RNARDX transcriptRadixin (RDX) mRNA

Degradation of RDX mRNA via RNA interference (siRNA) or RNase H-mediated cleavage (ASO), leading to reduced Radixin protein synthesis and subsequent inhibition of cytoskeletal-mediated tumor cell migration.